Skip to main content

Table 1 Registered trials for all diagnoses that are planned, accruing, or closed to accrual and incorporate TTFeilds

From: Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging

  Title Phase Status NCT Number
 Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM I Not yet recruiting NCT03705351
 NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma I Recruiting NCT03232424
 Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma I Recruiting NCT03223103
 Enhancing Optune Therapy With Targeted Craniectomy I Recruiting NCT02893137
 Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer I Active, not recruiting NCT02903069
 Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma I Recruiting NCT03477110
 TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma II Recruiting NCT02663271
 Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) II Recruiting NCT03405792
 Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma II Active, not recruiting NCT02743078
 A Phase II Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas II Recruiting NCT02507232
 Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma II Recruiting NCT02847559
 NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma II Recruiting NCT01894061
 Trial of Combination TTF (Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-Naive, Recurrent Glioblastoma II Recruiting NCT03430791
 A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM) II Recruiting NCT02343549
 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) III Completed NCT00916409
 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) III Completed NCT00379470
 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI IV Recruiting NCT03297125
 Optune (NOVOTTF-100A), Bevacizumab, & Hypofractionated Stereotactic Irradiation In Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) N/A Recruiting NCT01925573
 NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme N/A Recruiting NCT01954576
 TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM N/A Active, not recruiting NCT03780569
 Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma N/A Active, not recruiting NCT01892397
 Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma N/A Not yet recruiting NCT03530605
 Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma N/A Not yet recruiting NCT03450850
 NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma N/A Recruiting NCT03353896
 Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma N/A Recruiting NCT03033992
 Study of the NovoTTF-100 L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer I Not yet recruiting NCT03203525
 Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) I/II Active, not recruiting NCT01971281
 Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) II Recruiting NCT03606590
 Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) III Recruiting NCT03377491
 Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE/ENGOT-ov50) I/II Recruiting NCT02244502
 Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Platinum-resistant Ovarian Cancer (PROC) (ENGOT-ov50 / GOG-3029 / INNOVATE-3) N/A Recruiting NCT03940196
 NovoTTF-100 L in Combination With Pemetrexed (Alimta) for Advanced Non-small Cell Lung Cancer I/II Completed NCT00749346
 Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) II Completed NCT02397928
 Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) III Recruiting NCT02973789
 Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1–5 Brain Metastases Following Optimal Standard Local Treatment (COMET) II Active, not recruiting NCT01755624
 Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1–10 Brain Metastases Following Radiosurgery (METIS) III Recruiting NCT02831959
 Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer N/A Recruiting NCT03607682
 Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain (RAD 1704) N/A Recruiting NCT03488472
 Optune Device - TTField Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis II Not yet recruiting NCT03903640
  1. Abbreviations: CNS Central Nervous System, GI Gastrointestinal, GYN Gynecologic, LUNG Small-cell or Non-Small Cell Lung Cancer, METS Brain Metastases